CD8A and neoplasm: Finally, intratumoral administration of CCL5 increased the frequency of CCR5+ CD8+ T cells and mature CD11b+ NK cells within the tumor, and administration of CCL5 plus anti-PD-L1 (atezolizumab) induced tumor growth inhibition over anti-PD-L1 alone in the murine colon tumor model MC38.